Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10748552 | 0.88 | CA2 (0.39) | MAPTKLF10TDP1CA1CA12 | |
| SCHEMBL17008599 | 0.85 | KDM4E (0.39) | MAPTKLF10TDP1CA1CA12 | |
| SCHEMBL11231888 | 0.84 | TRPV1 (0.37) | MAPTKLF10TDP1CA1CA12 | |
| SCHEMBL14539258 | 0.83 | PDCD1 (0.39) | MAPTKLF10TDP1CA1CA12 | |
| SCHEMBL5610344 | 0.83 | PDCD1 (0.39) | MAPTKLF10TDP1PDE4APDE4B | |
| SCHEMBL12504376 | 0.83 | TRPV1 (0.43) | TDP1CA1CA12CA7CA9 | |
| SCHEMBL1836066 | 0.81 | CA1 (0.48) | MAPTCA1CA12CA7CA9 | |
| SCHEMBL22699664 | 0.81 | TAAR1 (0.39) | MAPTTDP1CA1CA12CA7 | |
| SCHEMBL69925 | 0.81 | TDP1 (0.52) | MAPTTDP1CA1CA12CA7 | |
| SCHEMBL29403778 | 0.81 | TDP1 (0.52) | MAPTTDP1CA1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915333-B1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSM IP ASSETS BV (NL) | 2015-06-03 | — | — | EP | disclosed |
| US-7601877-B2 | Condensation of a prenol or isoprenol with a hydroquinone or derivative in the presence of 0.005-1.0 mol percent of a Bronsted or Lewis acid catalyst selected from a bismuth, indium or Group 3 chloride, a heteropolyacid, and an NH- or a CH-acidic compound, oxidizing the ubihydroquinone; improved kinetics | DSM IP ASSETS B.V. (NL) | 2009-10-13 | — | — | US | disclosed |
| US-20080275275-A1 | Process for the Preparation of Ubihydroquinones and Ubiquinones | DSM IPASSETS B.V. (NL) | 2008-11-06 | — | — | US | disclosed |
| EP-1915333-A1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSMIP Assets B.V. (NL) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007017168-A1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSM IP ASSETS B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275275-A1 | Process for the Preparation of Ubihydroquinones and Ubiquinones | UBE2D3, UBE2L3, UBE2I | MAPT 2939/4885KLF10 4303/4885TDP1 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.